Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar 31;30(13):1497-505.
doi: 10.1038/onc.2010.548. Epub 2010 Dec 6.

Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies

C Schmidt  1 , M Bloomston, M H Shah
Affiliations
Review

Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies

C Schmidt et al. Oncogene. .

Abstract

Neuroendocrine tumors (NETs) are a complex group of malignancies with variable prognosis and response to treatment. For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies have demonstrated minimal activity. Current approaches for treatment of metastatic disease use a combination of loco-regional and targeted biological therapies. Clinical trials remain critical for evaluation of new and promising therapeutic options for patients with NETs.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Computed tomography (CT) scan imaging for neuroendocrine tumors. (a) Selected axial CT images of a patient with a large pancreatic primary neuroendocrine carcinoma and multiple hepatic metastases (top and bottom). (b) CT axial image after right lobar hepatic transarterial chemoembolization (TACE) for liver metastases (top) with three-dimensional reconstruction and subtracted view (bottom).
Figure 2
Figure 2
Octreoscan imaging for neuroendocrine tumors. Coronal octreoscan image demonstrating radiotracer uptake in multiple liver metastases and a large pancreatic primary neuroendocrine carcinoma. (b) Coronal octreoscan fusion images with single positron emission tomography (SPECT) providing increased anatomic detail. (c) Axial octreoscan fusion images with SPECT.
Figure 3
Figure 3
Histological subtypes of neuroendocrine tumors. (a) Microscopic section from a well-differentiated neuroendocrine carcinoma demonstrating low mitotic rate and low-grade bland histology. (b) Microscopic section from a poorly differentiated neuroendocrine carcinoma demonstrating high mitotic rate and high-grade histology similar in appearance to small cell carcinomas.
See this image and copyright information in PMC

References

    1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res. 2007;13:170–181. - PubMed
    1. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91:1543–1548. - PubMed
    1. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–132. - PubMed
    1. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008;26:963–970. - PubMed
    1. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol. 2002;13:614–621. - PubMed

MeSH terms

LinkOut - more resources